-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality (Vázquez-Sánchez et al., 2022). MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired in hospitals or in nursing homes, or community-associated MRSA (CA-MRSA) (CDC, 2019). MRSA remains highly prevalent due to several factors, including an increased number of immunocompromised and elderly patients, who are particularly vulnerable to infection, an increase...
-
Sector Analysis
NewAutomotive Exhaust Systems Market Trends, Sector Overview and Forecast to 2028
Automotive Exhaust Systems Market Report Overview The exhaust systems market size was 88.9 million units in 2023. The market declined over the historical period, primarily owing to the prolonged impact of COVID-19. Although the market is in a recovery phase it will post at a negative CAGR of more than 2% during 2023-2028. Innovations in exhaust system technology, such as exhaust after-treatment systems, automotive catalysts, and exhaust gas recirculation (EGR) systems, will increase demand for automotive exhaust systems, thereby driving...
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Sector Analysis
NewPolycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Report Overview Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. It stands as the most prevalent hormonal disorder affecting females of reproductive age. Genetic and environmental factors are responsible for the etiology of this condition. Unhealthy lifestyle choices, dietary habits, or exposure to infectious agents tend to increase the risk of developing PCOS. Key Mechanisms of Action...
-
Sector Analysis
NewFemale Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Report Overview Female sexual dysfunction (FSD) is an umbrella term that encompasses disorders of sexual desire, orgasm, arousal, and sexual pain that result in significant personal distress. FSD is a multifactorial, progressive problem that can occur at any stage of life. It is a complex neurovascular phenomenon that is under the control of psychological, neurovascular, and hormonal factors. Key Mechanisms of Action (Marketed) ·       Receptor Agonist ·       Enzyme Inhibitor ·       Receptor Antagonist...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Sector Analysis
Premature Labor (PL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Premature Labor (PL) Marketed and Pipeline Drugs Report Overview Premature/preterm labor (PL) is labor occurring after 20 and before 37 weeks gestation. Premature deliveries cause more than half of long-term morbidity and 75% of perinatal mortality. Premature labor is diagnosed primarily by history and symptoms. Symptoms of preterm labor include regular contractions before term gestational age associated with cervical change, pelvic pressure, menstrual-like cramps, watery vaginal discharge, and lower back pain. Although lower back pain is present in normal pregnancy as well,...